CoChat

Serglycin’s role in primary liver cancer: insights into tumor microenvironment and macrophage interaction

Open access
Lian, Qinghai, Ma, Chonghan, Wang, Xiaoxiao, Wang, Jiani, Zeng, Jindi, Zhang, Jiongshan, Li, Yongwei · 2025 · Frontiers in Immunology

The DOI matches its Crossref record; 70 of the 71 references it cites were found in a registry or an index.

Abstract

Background: Serglycin (SRGN) is an important proteoglycan that regulates tumorigenesis, but its role in primary liver cancer (PLC) remains unclear. Methods: We investigated the expression and prognostic potential of SRGN in PLC using bioinformatics analyses. HepG2 cells were transfected with an SRGN over expression vector and their proliferation, migration, invasion, resistance to sorafenib, and angiogenic capacity were examined in vitro . A subcutaneous xenograft tumor model was created using nude mice. SRGN overexpressing hepatoma cells were co-cultured with THP-1 derived macrophages. The expressions of CD80 and CD206, secretory molecules, and the NF-κB and STAT3 signal pathways were examined by flow cytometry, ELISA and western blot, respectively. Transwell migration and invasion were investigated in HepG2 and Huh7 co-cultured with SRGN-promoted macrophages. Results: Single-cell analysis revealed SRGN expression across 17 distinct cell subpopulations, with higher expression in macrophages in tumor tissues compared to those in normal tissues. SRGN displayed consistent high expression across cell cycle phases while exhibited dynamic expression during macrophage pseudotime trajectory. Cell communication analysis indicated that SRGN was involved in interactions within the tumor microenvironment (TME), particularly in the VEGF signaling network. Autocrine SRGN promoted in vitro aggressiveness, especially pro-angiogenic activity, and in vivo tumorigenicity of HepG2 cells, and conferred resistance to sorafenib. Paracrine SRGN promoted a partial polarization of TAMs toward an M2-like phenotype, accompanied by the activation of signaling pathways including NF-κB and STAT3. Levels of secreted argase1 and SRGN were increased in the supernatant. The invasion and migration of hepatoma cells were promoted by SRGN-overexpressing TAMs. Conclusions: Our findings highlight the role of SRGN in the TME of PLC. SRGN-high TAMs are induced by paracrine SRGN from hepatoma cells, establishing a self-reinforcing mechanism that drives PLC progression. Therapeutic strategies targeting SRGN should take into account its context-specific roles depending on TME cells.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2025.1668627

Cites

70 of 71 references verified1 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Single-cell analysis of SRGN expression in HCC. (A) The UMAP plot of all cells after quality control and standardization revealed 17 cell clusters marked with different colors. (B) The 17 clusters were annotated as 12 types of cells. (C) Feature plots showed SRGN expression across different cell types. (D) Comparative analysis of SRGN expression between HCC and normal group was presented in box plot. “*” denotes a p-value < 0.05.
Figure 1 Single-cell analysis of SRGN expression in HCC. (A) The UMAP plot of all cells after quality control and standardization revealed 17 cell clusters marked with different colors. (B) The 17 clusters were annotated as 12 types of cells. (C) Feature plots showed SRGN expression across different cell types. (D) Comparative analysis of SRGN expression between HCC and normal group was presented in box plot. “*” denotes a p-value < 0.05.CC BY · PubMed Central
Figure 2 SRGN expression and prognosis in monocyte/macrophage subsets in LIHC. GEPIA analysis using ANOVA test using TCGA/GTEx sub-datasets: (A) SRGN expression in LIHC tumor, LIHC normal and liver tissues grouped by cell type. (B) SRGN expression in monocyte/macrophage subsets grouped by tissue of LIHC tumor, LIHC normal and liver, respectively. TIMER analysis using the Cox proportional hazards model: (C–F) SRGN prognosis with monocyte, macrophageM1, M0 and M2 in LIHC.
Figure 2 SRGN expression and prognosis in monocyte/macrophage subsets in LIHC. GEPIA analysis using ANOVA test using TCGA/GTEx sub-datasets: (A) SRGN expression in LIHC tumor, LIHC normal and liver tissues grouped by cell type. (B) SRGN expression in monocyte/macrophage subsets grouped by tissue of LIHC tumor, LIHC normal and liver, respectively. TIMER analysis using the Cox proportional hazards model: (C–F) SRGN prognosis with monocyte, macrophageM1, M0 and M2 in LIHC.CC BY · PubMed Central
Figure 3 GSEA enrichment analysis for the SRGN. (A) Volcano plot for single gene differential analysis of SRGN. (B) Pathways upregulated in the high-SRGN group. (C) Pathways downregulated in the low-SRGN group. (D–I) Localization of different pathways in the single-cell dataset.
Figure 3 GSEA enrichment analysis for the SRGN. (A) Volcano plot for single gene differential analysis of SRGN. (B) Pathways upregulated in the high-SRGN group. (C) Pathways downregulated in the low-SRGN group. (D–I) Localization of different pathways in the single-cell dataset.CC BY · PubMed Central
Figure 4 The immune infiltration analysis of SRGN. (A) Correlation analysis results between SRGN and immune infiltrating cells. (B) Comparison of ssGSEA immune infiltrating cell proportions between high- and low-risk groups based on SRGN expression. (C) Correlation analysis of SRGN expression with immune checkpoint genes.
Figure 4 The immune infiltration analysis of SRGN. (A) Correlation analysis results between SRGN and immune infiltrating cells. (B) Comparison of ssGSEA immune infiltrating cell proportions between high- and low-risk groups based on SRGN expression. (C) Correlation analysis of SRGN expression with immune checkpoint genes.CC BY · PubMed Central
Figure 5 Cell cycling stage analysis. (A) PCA plots illustrate the cell cycle phases of the single-cell dataset. (B) UMAP of single-cell transcriptomes colored by cell cycle phase (G1/G2M/S) via Seurat’s CellCycleScoring. (C) Cell cycle distribution of different cells. (D) Cell cycling stage analysis of SRGN. HepG2-NC (E) and HepG2SG (F) cells were stained with Hoechst-33342, sorted into G1/S/G2/M populations, and subjected to qPCR (G). Axis ranges differ due to staining intensity but gates were set per sample based on DNA content.
Figure 5 Cell cycling stage analysis. (A) PCA plots illustrate the cell cycle phases of the single-cell dataset. (B) UMAP of single-cell transcriptomes colored by cell cycle phase (G1/G2M/S) via Seurat’s CellCycleScoring. (C) Cell cycle distribution of different cells. (D) Cell cycling stage analysis of SRGN. HepG2-NC (E) and HepG2SG (F) cells were stained with Hoechst-33342, sorted into G1/S/G2/M populations, and subjected to qPCR (G). Axis ranges differ due to staining intensity but gates were set per sample based on DNA content.CC BY · PubMed Central
Figure 6 Cell–cell communication analysis in HCC. (A) Circle diagram showing the number of cell communication interactions among different groups cell in the Normal group. (B) Circle diagram showing the number of cell communication interactions among different cell groups in the Tumor group. Cell-type to cell-type heatmap of VEGF signaling communication probabilities in normal (C) and tumor (D) groups. Difference and chord diagram of the VEGF signaling pathway between normal (E) and tumor (F) groups. Heatmaps of the VEGF signaling pathway network displaying the participation of each cell type in cell communication in normal (G) and tumor (H) groups. (I, J) Experimental validation of VEGF-A signaling. (I) VEGFA mRNA levels in lower-chamber M0 THP-1 macrophages after co-culture (****P < 0.001). (J) VEGF-A protein levels in 48-h co-culture supernatants measured by ELISA (****P < 0.001).
Figure 6 Cell–cell communication analysis in HCC. (A) Circle diagram showing the number of cell communication interactions among different groups cell in the Normal group. (B) Circle diagram showing the number of cell communication interactions among different cell groups in the Tumor group. Cell-type to cell-type heatmap of VEGF signaling communication probabilities in normal (C) and tumor (D) groups. Difference and chord diagram of the VEGF signaling pathway between normal (E) and tumor (F) groups. Heatmaps of the VEGF signaling pathway network displaying the participation of each cell type in cell communication in normal (G) and tumor (H) groups. (I, J) Experimental validation of VEGF-A signaling. (I) VEGFA mRNA levels in lower-chamber M0 THP-1 macrophages after co-culture (****P < 0.001). (J) VEGF-A protein levels in 48-h co-culture supernatants measured by ELISA (****P < 0.001).CC BY · PubMed Central
Figure 7 In vitro and in vivo experiments of pro-tumorigenicity of SRGN. (A) Relative expression of SRGN in HepG2, HepG2SG (overexpressing SRGN) and HepG2-NC (transfected with null vector control) examined by quantitative reverse transcription-polymerase chain reaction. (B) Expression of SRGN protein in HepG2, HepG2SG and HepG2-NC cells examined by western blot. (C) Proliferation rates (%) of HepG2, HepG2SG and HepG2-NC cells using CCK8 assay (*p < 0.05, **p < 0.01). (D) Proliferation rates (%) of HepG2SG and HepG2-NC cells treated with sorafenib, resistance index=1.15. (E) Invasion of HepG2SG and HepG2-NC cells examined by transwell assay (***p < 0.001). (F) Angiogenesis of HUVECs cultured with supernatant from HepG2SG and HepG2-NC cells, respectively (***p< 0.001). (G) Vasculogenic mimicry of HepG2SG and HepG2-NC cells (**p< 0.01). (H) Representative hematoxylin and eosin staining of tumor sections from mice xenograft with SRGN overexpressing HepG2SG and control cells. (I) Representative immunohistochemistry for CD34 and PAS staining and microvessel density. (J) Weight of HepG2SG and HepG2-NC subcutaneous xenograft tumors in nude mice (**p < 0.01). (K) Immunofluorescence staining of subcutaneous tumor tissues. Both SRGN and CD206 were up-regulated while CD80 was down-regulated in HepG2SG mice compared with HepG2-NC mice (*p < 0.05, **p < 0.01). Light blue: DAPI; green: fluorescein isothiocyanate-stained SRGN; red: CY3-stained CD80 or CD206.
Figure 7 In vitro and in vivo experiments of pro-tumorigenicity of SRGN. (A) Relative expression of SRGN in HepG2, HepG2SG (overexpressing SRGN) and HepG2-NC (transfected with null vector control) examined by quantitative reverse transcription-polymerase chain reaction. (B) Expression of SRGN protein in HepG2, HepG2SG and HepG2-NC cells examined by western blot. (C) Proliferation rates (%) of HepG2, HepG2SG and HepG2-NC cells using CCK8 assay (*p < 0.05, **p < 0.01). (D) Proliferation rates (%) of HepG2SG and HepG2-NC cells treated with sorafenib, resistance index=1.15. (E) Invasion of HepG2SG and HepG2-NC cells examined by transwell assay (***p < 0.001). (F) Angiogenesis of HUVECs cultured with supernatant from HepG2SG and HepG2-NC cells, respectively (***p< 0.001). (G) Vasculogenic mimicry of HepG2SG and HepG2-NC cells (**p< 0.01). (H) Representative hematoxylin and eosin staining of tumor sections from mice xenograft with SRGN overexpressing HepG2SG and control cells. (I) Representative immunohistochemistry for CD34 and PAS staining and microvessel density. (J) Weight of HepG2SG and HepG2-NC subcutaneous xenograft tumors in nude mice (**p < 0.01). (K) Immunofluorescence staining of subcutaneous tumor tissues. Both SRGN and CD206 were up-regulated while CD80 was down-regulated in HepG2SG mice compared with HepG2-NC mice (*p < 0.05, **p < 0.01). Light blue: DAPI; green: fluorescein isothiocyanate-stained SRGN; red: CY3-stained CD80 or CD206.CC BY · PubMed Central
Figure 8 The SRGN mRNA expression in THP-1 cells, M0 macrophages, M1 and M2 macrophages, as well as TAM1 and TAM2. SRGN mRNA levels were significantly different among monocyte/macrophages (**p < 0.01). Tumor -associated macrophages 1(TAM1): M0 co-cultured with HepG2-NC, TAM2: M0 co-cultured with SRGN overexpressing HepG2SG. NS: no significant difference.
Figure 8 The SRGN mRNA expression in THP-1 cells, M0 macrophages, M1 and M2 macrophages, as well as TAM1 and TAM2. SRGN mRNA levels were significantly different among monocyte/macrophages (**p < 0.01). Tumor -associated macrophages 1(TAM1): M0 co-cultured with HepG2-NC, TAM2: M0 co-cultured with SRGN overexpressing HepG2SG. NS: no significant difference.CC BY · PubMed Central
Figure 9 (A) CD80 and CD206 examined by flow cytometry in M2 macrophages, TAM1 and TAM2 (**p < 0.01, *p < 0.05). (B) SRGN, Arg1, NOS2, IL-1β and MMP9 were examined by ELISA in supernatants of M2 macrophages, TAM1 and TAM2 (**p<0.01, *p < 0.05); (C) NF-κB, Stat3 and phosphorylation in M2 macrophages, TAM1 and TAM2 (**p<0.01, *p<0.05). NS: no significant difference. (D) Cell proliferation of HepG2 and Huh7 cells induced by TAM1 and TAM2 respectively (**, ##p<0.01, # p<0.05). (E) Transwell migration of HepG2 and Huh7 cells induced by TAM1 and TAM2 respectively (**, ##p<0.01). (F) Transwell invasion of HepG2 and Huh7 cells induced by TAM1 and TAM2 respectively (**, ##p<0.01).
Figure 9 (A) CD80 and CD206 examined by flow cytometry in M2 macrophages, TAM1 and TAM2 (**p < 0.01, *p < 0.05). (B) SRGN, Arg1, NOS2, IL-1β and MMP9 were examined by ELISA in supernatants of M2 macrophages, TAM1 and TAM2 (**p<0.01, *p < 0.05); (C) NF-κB, Stat3 and phosphorylation in M2 macrophages, TAM1 and TAM2 (**p<0.01, *p<0.05). NS: no significant difference. (D) Cell proliferation of HepG2 and Huh7 cells induced by TAM1 and TAM2 respectively (**, ##p<0.01, # p<0.05). (E) Transwell migration of HepG2 and Huh7 cells induced by TAM1 and TAM2 respectively (**, ##p<0.01). (F) Transwell invasion of HepG2 and Huh7 cells induced by TAM1 and TAM2 respectively (**, ##p<0.01).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 71 references

Research works printed but not linked: 1

  1. Li, 2013, Expression of serglycin in HepG2 cells with different HBV infection status

Cited by

See all 11

Metadata

Authors
Lian, Q., Ma, C., Wang, X., Wang, J., Zeng, J., Zhang, J., & Li, Y.
Affiliations
  • Sun Yat-sen University (CN)
  • Third Affiliated Hospital of Sun Yat-sen University (CN)
  • First Affiliated Hospital of Guangzhou Medical University (CN)
Corresponding author
  • Zeng, Jindi
  • Zhang, Jiongshan
  • Li, Yongwei
Venue
Frontiers in Immunology
Published
2025-12-16
Volume
16
Pages
1668627-1668627
ISSN
1664-3224 (ISSN-L)
OpenAlex
W4417356273
Cited by
10
References
67
Citations by year
2026: 10
FWCI
4.99
Type
journal article
Language
en
Open access
Locations
  • Frontiers in Immunology (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by)
Funders
  • Universidade de Macau
  • Basic and Applied Basic Research Foundation of Guangdong Province
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Proteoglycans and glycosaminoglycans research
  • Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
  • Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
Keywords
serglycin, primary liver cancer, hepatocellular carcinoma, tumor microenvironment, tumor-associated macrophages, TAM polarization, M2 macrophages, NF-κB signaling, STAT3 signaling, sorafenib resistance, angiogenesis, VEGF signaling, proteoglycans, prognostic factors
MeSH terms
Tumor-Associated Macrophages, Animals, Cell Communication, Cell Movement, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Macrophages, Male, Mice, Nude, Proteoglycans, Signal Transduction, Vesicular Transport Proteins, Cell Line, Tumor, Cell Proliferation, Mice, Hep G2 Cells, Tumor Microenvironment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Serglycin’s role in primary liver cancer: insights into tumor microenvironment and macrophage interaction. https://app.cochat.ai/papers/10.3389/fimmu.2025.1668627
The paper
Lian, Q., Ma, C., Wang, X., Wang, J., Zeng, J., Zhang, J., & Li, Y. (2025). Serglycin’s role in primary liver cancer: insights into tumor microenvironment and macrophage interaction. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2025.1668627

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.